Chronic lymphocytic leukaemia: from genetics to treatment

@article{Bosch2019ChronicLL,
  title={Chronic lymphocytic leukaemia: from genetics to treatment},
  author={Francesc Bosch and Riccardo Dalla‐Favera},
  journal={Nature Reviews Clinical Oncology},
  year={2019},
  pages={1-18}
}
Chronic lymphocytic leukaemia (CLL), the most frequent type of leukaemia in adults, is a lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature CD5+CD23+ B cells in the peripheral blood, secondary lymphoid tissues and bone marrow. CLL is an incurable disease with a heterogeneous clinical course, for which the treatment decision still relies on conventional parameters (such as clinical stage and lymphocyte doubling time). During the past 5 years, relevant… Expand
Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia.
  • Jimmy Lee, Y. Lynn Wang
  • Medicine
  • The Journal of molecular diagnostics : JMD
  • 2020
TLDR
This article focuses on the prognostic and predictive molecular biomarkers in CLL relevant to the molecular pathology practice, beginning with a review of well-established prognostic markers that have already been incorporated into major clinical guidelines which will be followed by a discussion of emerging biomarkers that are expected to impact clinical practice soon in the future. Expand
The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment
TLDR
There has been an impressive explosion of new approaches based on targeted therapies for CLL patients during the last decade, and next-generation sequencing identified an unprecedented number of gene mutations with potential prognostic and predictive value. Expand
[Chronic lymphocytic leukemia].
TLDR
Therapy is only required if there are pronounced symptoms or changes in the blood count, such as a relevant drop in hemoglobin and/or platelets, and the prognosis strongly depends on the individual molecular and cytogenetic risk factors. Expand
Chronic lymphocytic leukemias with trisomy 12 show a distinct DNA methylation profile linked to altered chromatin activation.
TLDR
Chronic lymphocytic leukemias with trisomy 12 show a distinct DNA methylation profile linked to altered chromatin activation. Expand
Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
TLDR
This study sought to investigate if the causes of death in patients with newly diagnosed CLL would differ according to the CLL-IPI risk group, which integrates major clinical and molecular prognostic factors into a single risk score. Expand
Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
TLDR
A woman in her 70s, diagnosed with CLL/SLL in 2000, untreated, who subsequently presented 12 years later with de novo CML, BCR-ABL1+. Expand
Recent advances in chronic lymphocytic leukemia therapy
  • J. Uhm
  • Medicine
  • Blood research
  • 2020
TLDR
This review will focus on the risk stratification and the management of CLL in the era of novel small molecules. Expand
Advances in Epigenetics and Epigenomics in Chronic Lymphocytic Leukemia
TLDR
The potential of CLL epigenomics for predicting treatment response and resistance is mounting, especially with the advent of novel targeted CLL therapies. Expand
Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients
TLDR
Clonal evolution and genomic alterations in the Eµ-TCL1 mouse model mirror human CLL and identify Myc as oncogenic hit associated with disease progression in patients. Expand
Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
TLDR
It is demonstrated that the interaction with the immune microenvironment plays a key role in clinical progression in CLL, thereby providing a rationale for the use of early immunotherapeutic intervention. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 253 REFERENCES
Non-coding recurrent mutations in chronic lymphocytic leukaemia
TLDR
An integrated portrait of the CLL genomic landscape is provided, new recurrent driver mutations of the disease are identified, and clinical interventions that may improve the management of this neoplasia are suggested. Expand
Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management
TLDR
A state of the art review on the prevalence, nomenclature, biology, natural history and clinical management of MBL is provided. Expand
Acquired initiating mutations in early hematopoietic cells of CLL patients.
TLDR
This work indicates that CLL develops from pre-leukemic multipotent hematopoietic progenitors carrying somatic mutations, and advocates for abnormalities in early B-cell differentiation as a phenotypic convergence of the diverse acquired mutations observed in CLL. Expand
Progress in chronic lymphocytic leukaemia: a historical perspective.
  • K. Rai
  • Medicine
  • Bailliere's clinical haematology
  • 1993
A historical review of gains in the body of knowledge on chronic lymphocytic leukaemia (CLL) reveals a continuous, steady process from the beginning of the century with the pioneering work ofExpand
The molecular pathogenesis of chronic lymphocytic leukaemia
TLDR
This Review focuses on recent insights into the understanding of CLL biology, with emphasis on the role of genetic lesions in the initiation and clinical progression of Cll. Expand
Small Lymphocytic Lymphoma and Chronic Lymphocytic Leukemia: Are They the Same Disease?
TLDR
There is still a lack of knowledge on the precise biological basis underlying the different clinical presentations of CLL and SLL, but it is expected that future studies will shed light on the pathophysiology of both disorders. Expand
MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene
TLDR
MyD88 mutations exclusively in the IGHV-mutated CLL cases were analyzed to explore its prognostic value and to confirm the AS-PCR assay and to detect MYD 88 mutations other than L265P. Expand
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
TLDR
The authors report on transcriptional changes in CLL patients treated with ibrutinib and identify early clonal shifts associated with evolution of resistant clones, indicating greater evolutionary capacity, heralding the emergence of drug-resistant clones. Expand
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
TLDR
The patterns of somatic mutation, supported by functional and clinical analyses, strongly indicate that the recurrent NOTCH1, MYD88 and XPO1 mutations are oncogenic changes that contribute to the clinical evolution of the disease. Expand
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL.
TLDR
Findings indicate that LC-MBL may not represent a true preleukemic condition, thus differing from HC-Mbl/CLL-0 in which the identification of factors endowing malignant potential is strongly warranted. Expand
...
1
2
3
4
5
...